Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.
about
A New Concept of Enhancing Immuno-Chemotherapeutic Effects Against B16F10 Tumor via Systemic Administration by Taking Advantages of the Limitation of EPR EffectAn enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy.Mannosylation of virus-like particles enhances internalization by antigen presenting cellsThe non-pathogenic Australian rabbit calicivirus RCV-A1 provides temporal and partial cross protection to lethal Rabbit Haemorrhagic Disease Virus infection which is not dependent on antibody titres.Nanoscale assemblies and their biomedical applications.Immunosuppressive roles of natural killer T (NKT) cells in the skin.Antigen delivery by virus-like particles for immunotherapeutic vaccination.Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses.Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Multi-target chimaeric VLP as a therapeutic vaccine in a model of colorectal cancer.Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.Optimization of norovirus virus-like particle production in Pichia pastoris using a real-time near-infrared bioprocess monitor.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Secretion and assembly of calicivirus-like particles in high-cell-density yeast fermentations: strategies based on a recombinant non-specific BPTI-Kunitz-type protease inhibitor.Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.Virus like particles as a platform for cancer vaccine development.
P2860
Q27300754-02CD7ABB-EAD2-4E81-B462-3CC39FEC05F7Q31121276-22E61C7C-DE2A-4050-9194-E36A63CE75C7Q35224806-7A5DCDE9-A4CA-4707-A075-CEEA1AC76E1BQ37071420-18762FDA-1B88-4A08-BB10-E186E371B6EDQ38072847-FC23BB4A-EA14-4FC2-8252-85231F26E9CEQ38209646-8502B56B-2EEB-4A2E-87D6-AF1946E0C217Q38285854-3EB6EC65-D702-435F-92F3-C6A1AC4DA7DBQ38554795-B5EBF563-010F-4DCA-BF12-CEEAB17C2A84Q38564323-AB4E18DB-32CD-4F91-A6B3-BF21CD022868Q38618258-3A1A332E-02A5-47BE-9355-8E6358840359Q38621219-916F06C3-E083-4221-9AC6-8FF76358D2F8Q39049093-1B0623DD-BAE4-445D-900F-49184DBB6BF3Q40988893-70E2C6F6-99A3-48FD-9701-5E0FEA52340AQ41139823-DBE7C972-DC9D-4A24-B76D-EF1AB2AA995FQ42181296-EF746264-FF80-43A8-BBAA-E5019BE5B32AQ43555934-4BB43550-F88F-4710-90B2-6DFDEB362F6FQ45324534-3B5198AB-7953-4BB6-8778-EDD8A0173C47
P2860
Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@en
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@nl
type
label
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@en
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@nl
prefLabel
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@en
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@nl
P2093
P1476
Virus-like particles and α-gal ...... elicits anti-tumor responses.
@en
P2093
Colin M Hayman
Fiona Clow
Margaret A Baird
Sara J McKee
Sarah L Young
Vivienne L Young
P304
P356
10.1016/J.JCONREL.2012.02.015
P407
P577
2012-02-22T00:00:00Z